4//SEC Filing
Sabzevari Helen 4
Accession 0001415889-24-010426
CIK 0001797768other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:55 PM ET
Size
10.1 KB
Accession
0001415889-24-010426
Insider Transaction Report
Form 4
Sabzevari Helen
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2024-04-03−25,000→ 0 totalExercise: $3.48Exp: 2033-06-12→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−20,250→ 0 totalExercise: $8.38Exp: 2032-06-13→ Common Stock (20,250 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−40,501→ 0 totalExercise: $24.38Exp: 2031-06-24→ Common Stock (40,501 underlying)
Footnotes (1)
- [F1]This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Documents
Issuer
Kinnate Biopharma Inc.
CIK 0001797768
Entity typeother
Related Parties
1- filerCIK 0001724195
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:55 PM ET
- Size
- 10.1 KB